News & Updates

The incidence of prostate cancer is reduced among individuals treated with salbutamol, a short-acting beta-2 adrenergic agonist, according to a study.

Use of belzutifan, a first-in-class hypoxia-inducible factor subunit 2α (HIF-2α) inhibitor, in patients with advanced clear cell renal cell carcinoma (RCC) is effective in either the 120- or the 200-mg dose, a phase II study has shown. Both doses are also safe.

Treatment with osimertinib following chemoradiotherapy (CRT) helps lower the risk of distant metastases and central nervous system (CNS) disease progression in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) nonsmall cell lung cancer (NSCLC), results of the phase III LAURA study have shown.

The addition of CDK4/6 inhibitor ribociclib to palliative radiotherapy is relatively safe in patients with metastatic breast cancer, reports a study.